Fimea issues a reminder: Emerade adrenaline pens should be returned to a pharmacy
On 11 May 2023, Fimea announced the recall of Emerade adrenaline pens. The press release stated that all strengths and lots of the product are recalled from consumers as a precautionary measure. However, the recall does not apply to 150 microgram (µg) lots. The 150 µg pens have not been distributed in Finland since 2019 and will be expired in any case.
The recall applies to 300 µg or 500 µg Emerade adrenaline pens. They are recalled by the marketing authorisation holder Pharma Swiss Česká republika s.r.o. as a precautionary measure. Tests conducted on the adrenaline pens have revealed cases where the pen has not worked properly. The dose fails to inject, or it is injected prematurely.
Medication users who are in possession of an Emerade 300 µg or 500 µg adrenaline pen must return the product to a pharmacy. The pen is not an interchangeable product. To receive a substituting product, patients must have a prescription for the substitute product from the attending physician. Patients must acquire a new adrenaline pen before returning the Emerade pen to a pharmacy.
If you have an Emerade adrenaline pen:
- Contact your attending physician to get a prescription for a substitute product.
- Before returning the pen, make sure you have acquired a substitute product.
- Return the Emerade pen to a pharmacy.